ArticleBMC oral health2025
The impact of catalpol on osteogenic differentiation of the jaw bone marrow mesenchymal stem cells on the basis of network pharmacology, molecular docking and experimental validation.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe research aims to explore the effects of catalpol on the osteogenic differentiation of Jaw Bone Marrow Mesenchymal Stem Cells(JBMMSCs).
methodsThe study employed network pharmacology, molecular docking, and in vitro experiments.Potential drug targets were identified through databases, and a protein-protein interaction network was constructed.Gene Ontology and KEGG analyses were conducted on the overlapping targets. Molecular docking was used to confirm the binding of catalpol to core targets. In vitro, JBMMSCs were utilized to investigate the effects of catalpol on the osteogenesis of the cells via CCK-8 assays, ALP staining, Alizarin Red S staining, WB and RT-PCR.
resultsA total of 99 common therapeutic targets of catalpol for bone defect regeneration were identified. Protein-protein interaction (PPI) Network analysis screened 10 core target proteins: ALB, EGFR, ESR1, HSP90AA1, PPARG, SRC, RHOA, GSK3B, SERPINE1, and KDR. Gene Ontology (GO) and Functional analyses revealed 161 biological processes (BP), 38 cellular components (CC), and 59 molecular functions (MF) associated with Catalpol-mediated bone defect repair. KEGG pathway enrichment analysis demonstrated that the target genes were primarily enriched in 16 signaling pathways, notably including osteoclast differentiation, apoptosis, and metabolic pathways. Molecular docking results indicated that catalpol exhibited binding energies < -5 kcal·mol⁻¹ with key target proteins (ALB, EGFR, ESR1, HSP90AA1, and PPARG). The vivo experiments demonstrated that catalpol (0.1µM、1µM、10µM、20µM concentration range) promoted the proliferation of JBMMSCs. Catalpol significantly enhanced alkaline phosphatase (ALP) activity, ALP expression, and osteogenic Mineralization in JBMMSCs, with 1 µM exhibiting the most pronounced effect (p < 0.05). Furthermore, 1 µM catalpol upregulated the expression of osteogenesis-related proteins (BMP-2, RUNX2, and OCN) and their Corresponding mRNA transcripts in JBMMSCs. The most significant regulatory Effects were observed at 72 h post-treatment (p < 0.05).
conclusionCatalpol enhances alveolar bone defect regeneration by regulating multiple genes and pathways. Studies have shown that catalpol boosts the proliferation and osteogenic differentiation/mineralization of JBMMSCs and increases the expression of osteogenesis-related genes and proteins. The ideal concentration for ex vivo induction was identified as 1 μM in this investigation. These results establish a scientific foundation for the potential use of catalpol in osteogenesis therapy, although additional research is necessary to clarify its clinical effectiveness and mechanisms of action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.